CORD-19:68a7101a90454172c91785d8c352f776a82df5d4 / 524296-524597 3 Projects
Annnotations
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T71580 | 0-301 | Sentence | denotes | A phase 2 clinical trial (CAMMS-223) has shown the lymphocytedepleting humanised monoclonal antibody alemtuzumab to be highly effective in the treatment of early relapsing-remitting multiple sclerosis; reducing the risk of relapse and accumulation of disability by N70% compared to interferon beta-1a. |